Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises TeleComputing in conjunction with the sale of Kentor
Mandate

Vinge advises TeleComputing in conjunction with the sale of Kentor

June 28, 2017

Vinge, together with the Norwegian law firm Wiersholm, has advised TeleComputing, a portfolio company to IK VII fund, in conjunction with the sale of the Kentor Group to Norwegian Sopra Steria.

Kentor is a fast growing IT consultancy company with approximately 330 employees which has grown since its formation in 1983 to become a successful IT company with offices in Stockholm, Gothenburg and St. Petersburg. Kentor provides services within, among other things, transformation, system integration and systems development.

Vinge’s team consisted of, among others, Jonas Bergström, Joacim Rydergård, Karl Klackenberg and Anna Hellohf.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024